Diabetes Mellitus Type 1

Diabetes Mellitus Type 1 – High‑Yield Study Guide for Medical Students

Definition

Type 1 Diabetes Mellitus (T1DM) is a chronic autoimmune disease characterized by T‑cell–mediated destruction of pancreatic β‑cells, leading to absolute insulin deficiency, hyperglycemia, and dependence on exogenous insulin for survival. It typically presents in childhood or young adulthood but can occur at any age.

Epidemiology

Understanding the epidemiology of T1DM is important for exam questions and clinical reasoning:

• Age of onset: Bimodal peaks in childhood (4–6 years) and early puberty (10–14 years), but adult-onset T1DM and LADA (latent autoimmune diabetes in adults) are increasingly recognized.
• Incidence: Varies widely by geography and ethnicity; highest in Northern Europe and Scandinavia, lower in East Asia and South America.
• Sex: Mild male predominance in many populations, but varies.
• Genetic predisposition: Strong association with HLA class II alleles (e.g., HLA‑DR3, DR4, DQ2, DQ8) but overall concordance in monozygotic twins is only ~30–50%, highlighting environmental contribution.
• Environmental factors: Viral infections (e.g., enteroviruses), early dietary exposures, microbiome, and vitamin D status are implicated, but causality is not fully established.

Pathophysiology

The core pathophysiology of T1DM is autoimmune β‑cell destruction leading to absolute insulin deficiency and a tendency to ketoacidosis.

Autoimmunity and β‑Cell Destruction

• Genetic susceptibility: Certain HLA haplotypes (DRB1*03, DRB1*04, DQB1*02, DQB1*0302) confer increased risk by altering antigen presentation of β‑cell peptides to CD4+ T cells.
• Initiation: An environmental trigger in a genetically predisposed host leads to loss of tolerance to β‑cell antigens (e.g., insulin, GAD65, IA‑2, ZnT8).
• Cellular immunity: CD4+ and CD8+ T lymphocytes infiltrate pancreatic islets (insulitis), leading to progressive destruction of β‑cells via cytotoxic mechanisms and cytokine-mediated damage (e.g., IL‑1β, TNF‑α, IFN‑γ).
• Humoral immunity: Autoantibodies (GAD65, IA‑2, IAA, ZnT8) serve as markers of autoimmunity and risk but are not necessarily the primary mediators of β‑cell destruction.

Metabolic Consequences of Absolute Insulin Deficiency

• Glucose metabolism:
  • ↓ Peripheral glucose uptake (muscle and adipose tissue) due to lack of insulin.
  • ↑ Hepatic gluconeogenesis and glycogenolysis driven by unopposed glucagon and counter-regulatory hormones.
  • Result: Marked fasting and postprandial hyperglycemia, osmotic diuresis, volume depletion, and electrolyte loss.
• Lipid metabolism:
  • Insulin normally inhibits hormone-sensitive lipase; its absence → ↑ lipolysis.
  • ↑ Free fatty acid (FFA) flux to the liver → β‑oxidation → overproduction of ketone bodies (acetoacetate, β‑hydroxybutyrate).
  • Accumulation of ketone bodies → metabolic acidosis (diabetic ketoacidosis, DKA).
• Protein metabolism:
  • Insulin deficiency → ↑ proteolysis and negative nitrogen balance, contributing to weight loss and growth impairment in children.
• Counter-regulatory hormones:
  • Glucagon, catecholamines, cortisol and growth hormone are relatively unopposed, amplifying hyperglycemia and ketogenesis.

Clinical Presentation

T1DM often presents acutely over days to weeks; however, a more insidious onset can occur, particularly in older patients or those in the “honeymoon” period.

Classic Symptoms

• Polyuria: Due to osmotic diuresis from hyperglycemia exceeding renal threshold (~180 mg/dL / ~10 mmol/L).
• Polydipsia: Secondary to volume depletion and hyperosmolarity.
• Polyphagia: Despite weight loss, due to cellular energy deprivation and catabolic state.
• Weight loss: Due to loss of calories in the urine and catabolism of fat and muscle.
• Fatigue and lethargy: From hyperglycemia, dehydration, and catabolism.

Diabetic Ketoacidosis (DKA) Presentation

DKA is a common initial presentation in children and adolescents and an important exam topic.

• Symptoms: Nausea, vomiting, abdominal pain (may mimic acute abdomen), anorexia.
• Signs:
  • Kussmaul respirations (deep, rapid breathing) due to metabolic acidosis.
  • Fruity or acetone breath odor.
  • Signs of dehydration (dry mucous membranes, tachycardia, hypotension, poor skin turgor).
  • Altered mental status, ranging from mild confusion to coma in severe cases.
• Precipitating factors: Infection, missed insulin doses, new-onset diabetes, myocardial infarction, trauma, or other physiological stress.

Other Clinical Features

• Enuresis in a previously dry child: Red flag for T1DM.
• Blurred vision: Due to osmotic changes in the lens.
• Candidal infections: Recurrent genital or skin candidiasis may be the first manifestation.
• Associated autoimmune diseases: Autoimmune thyroid disease, celiac disease, pernicious anemia, Addison disease; may be present at diagnosis or develop later.

Diagnosis

The diagnostic criteria for diabetes are the same for T1DM and T2DM; classification relies on clinical and laboratory features.

Diagnostic Criteria for Diabetes Mellitus

Diagnosis of diabetes can be made using any one of the following (preferably confirmed on a separate day unless unequivocal hyperglycemia with classic symptoms is present):

• Fasting plasma glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L) after at least 8 hours of fasting.
• 2‑hour plasma glucose ≥ 200 mg/dL (11.1 mmol/L) during a 75‑g oral glucose tolerance test (OGTT).
• HbA1c ≥ 6.5% (48 mmol/mol), measured by standardized assay.
• Random plasma glucose ≥ 200 mg/dL (11.1 mmol/L) in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis.

Distinguishing Type 1 from Type 2 Diabetes

In many patients, especially children and lean young adults, classification is clinically straightforward, but borderline cases require additional testing.

• Clinical clues to T1DM:
  • Younger age at onset (classically <30 years, but not exclusive).
  • Lean or normal BMI; absence of metabolic syndrome features.
  • Rapid symptom onset, ketosis or DKA at presentation.
  • Personal or family history of autoimmune disease.
• Laboratory tests:
  • Autoantibodies: Presence of one or more is strongly supportive of T1DM.
    • GAD65 antibodies (anti‑glutamic acid decarboxylase).
    • IA‑2 (insulinoma-associated protein 2) antibodies.
    • ZnT8 (zinc transporter 8) antibodies.
    • Insulin autoantibodies (IAA; more common in children).
  • C‑peptide: Low or undetectable fasting and stimulated C‑peptide levels suggest severe β‑cell failure consistent with T1DM.
  • Ketosis: Presence of urine or serum ketones at diagnosis supports T1DM but is not exclusive.

Laboratory Evaluation at Diagnosis

Initial workup should include:

• Plasma glucose, electrolytes, BUN, creatinine, and venous blood gas (if DKA suspected).
• Serum and/or urine ketones (preferably β‑hydroxybutyrate).
• Complete blood count and infection screen if indicated.
• Baseline lipid profile, liver function tests, and thyroid function tests.
• Screening for associated autoimmunity (e.g., TSH with anti‑TPO, tissue transglutaminase IgA for celiac disease) per guidelines.

Management Overview

Management of T1DM is centered on lifelong insulin replacement, structured education, and prevention of acute and chronic complications. Treatment must be individualized but follows consistent principles.

Glycemic Targets

• General adult target: HbA1c < 7% for most nonpregnant adults, with less stringent goals in those at high risk of hypoglycemia or with limited life expectancy.
• Children and adolescents: Individualized targets, often in the <7.0–7.5% range depending on age, risk of hypoglycemia, and resources.
• Pregnancy: Tighter control required (typical target HbA1c < 6–6.5% if achievable without severe hypoglycemia).

Insulin Therapy

T1DM requires exogenous insulin therapy from diagnosis. Physiologic replacement uses a basal–bolus strategy or continuous subcutaneous insulin infusion (CSII) via pump.

Types of Insulin

• Rapid‑acting analogs: Lispro, aspart, glulisine.
  • Onset: ~10–20 minutes; peak: 1–3 hours; duration: 3–5 hours.
  • Used as prandial (bolus) insulin and for correction dosing.
• Short‑acting insulin: Regular insulin.
  • Onset: 30–60 minutes; peak: 2–4 hours; duration: 6–8 hours.
  • Can be used IV in DKA; less convenient for routine prandial dosing due to slower onset.
• Intermediate‑acting insulin: NPH.
  • Onset: 1–2 hours; peak: 4–12 hours; duration: 12–18 hours.
  • Used as basal insulin in some regimens but has pronounced peak and higher hypoglycemia risk.
• Long‑acting basal analogs: Glargine, detemir, degludec (ultra‑long acting).
  • Provide relatively peakless basal coverage over 20–42 hours, depending on preparation.
  • Preferred for physiologic basal replacement and more stable glycemic control.

Basal–Bolus Regimen (Multiple Daily Injections)

• Basal insulin: Typically once daily long‑acting analog (glargine, degludec) or twice‑daily detemir; accounts for ~40–50% of total daily insulin dose.
• Bolus (prandial) insulin: Rapid‑acting analog before meals; total daily dose split across 3 main meals (and snacks if needed).
• Starting total daily dose (TDD): Often ~0.4–0.6 units/kg/day in adults with new-onset T1DM; lower in honeymoon phase and higher in puberty or illness.
• Carbohydrate counting: Insulin‑to‑carbohydrate ratio (e.g., 1 unit per 10–15 g carbohydrate) plus correction factor for premeal hyperglycemia are used to fine-tune doses.

Insulin Pump Therapy (CSII)

• Delivers only rapid‑acting insulin with adjustable basal rates and bolus doses.
• Allows precise tailoring of basal delivery (e.g., different rates overnight vs daytime).
• Can be integrated with continuous glucose monitoring (CGM) systems, including hybrid closed-loop (“artificial pancreas”) systems that automatically modulate insulin delivery based on sensor glucose.

Glucose Monitoring

• Self‑monitoring of blood glucose (SMBG):
  • Fingerstick measurements multiple times daily: pre-meal, bedtime, occasionally 2 hours post-meal, and during illness or suspected hypoglycemia.
• Continuous glucose monitoring (CGM):
  • Real‑time or intermittently scanned sensors measure interstitial glucose every few minutes.
  • Improves detection of nocturnal and asymptomatic hypoglycemia.
  • Increasingly standard of care in T1DM, particularly in children and patients with hypoglycemia unawareness.

Hypoglycemia Management and Education

Hypoglycemia is the major acute complication of insulin therapy and a key focus in OSCEs and exams.

• Definition: Typically glucose <70 mg/dL (3.9 mmol/L); severe hypoglycemia involves cognitive impairment requiring assistance.
• Symptoms:
  • Autonomic: Tremor, palpitations, anxiety, sweating, hunger, paresthesias.
  • Neuroglycopenic: Confusion, irritability, blurred vision, seizures, loss of consciousness.
• Treatment:
  • Conscious patient: 15–20 g of fast‑acting carbohydrate (e.g., glucose tablets, juice) and recheck in 15 minutes (“rule of 15”).
  • Severe or unconscious: Glucagon (IM/SC or nasal) or IV dextrose in a medical setting.
• Prevention:
  • Adjust insulin during exercise, illness, or meal changes.
  • Individualize glycemic targets in patients with recurrent hypoglycemia or hypoglycemia unawareness.

Management of Diabetic Ketoacidosis (DKA) – Brief Overview

Full DKA management is a dedicated topic; here is a high-yield outline.

• Key components:
  • Aggressive fluid resuscitation with isotonic saline.
  • Regular insulin IV infusion with a fixed-rate protocol.
  • Careful potassium and electrolyte management (insulin drives K+ into cells; total body potassium is depleted).
  • Bicarbonate therapy reserved for severe acidosis (e.g., pH < 6.9) per local protocol.
  • Identification and treatment of precipitating cause (e.g., infection, missed insulin).

Screening and Management of Chronic Complications

Chronic complications correlate with duration and degree of hyperglycemia; early and sustained glycemic control reduces risk.

Microvascular Complications

• Diabetic retinopathy:
  • Nonproliferative: Microaneurysms, dot-blot hemorrhages, hard exudates, cotton-wool spots.
  • Proliferative: Neovascularization, vitreous hemorrhage, traction retinal detachment.
  • Screening: Dilated eye exam starting 3–5 years after onset of T1DM (in adults) and annually thereafter; earlier in puberty or longer duration.
• Diabetic nephropathy:
  • Earliest marker is moderately increased albuminuria (microalbuminuria) before decline in eGFR.
  • Screening: Annual urine albumin-to-creatinine ratio and eGFR starting 5 years after diagnosis in adults; timing in children individualized.
  • Management: ACE inhibitors or ARBs in patients with albuminuria; blood pressure and glycemic control.
• Diabetic neuropathy:
  • Distal symmetric polyneuropathy: Stocking-glove sensory loss, burning, tingling, decreased vibration sense.
  • Autonomic neuropathy: Orthostatic hypotension, gastroparesis, bladder dysfunction, erectile dysfunction.
  • Screening: Annual foot exams, monofilament testing, assessment of vibratory sensation and ankle reflexes.

Macrovascular Complications

• Cardiovascular disease: Premature atherosclerosis with increased risk of MI and stroke; risk accentuated by smoking, hypertension, dyslipidemia.
• Peripheral arterial disease: Claudication, poor wound healing, critical limb ischemia.
• Prevention: Lipid management (statins in appropriate age/risk groups), blood pressure control, smoking cessation, and lifestyle modification.

Comprehensive Care and Lifestyle

• Nutrition:
  • Structured medical nutrition therapy with emphasis on carbohydrate counting, consistent meal timing, and balanced macronutrient intake.
  • Avoid excessive simple sugars; focus on whole grains, vegetables, lean protein, and healthy fats.
• Physical activity:
  • Encouraged for cardiovascular and metabolic benefits.
  • Insulin and carbohydrate adjustments are often needed to prevent exercise-induced hypoglycemia.
• Education and psychosocial support:
  • Diabetes self-management education (DSME) is essential: insulin administration, glucose monitoring, sick-day rules, hypoglycemia management.
  • Psychosocial assessment for diabetes distress, depression, and adherence issues.
• Vaccinations:
  • Ensure routine immunizations; adults should receive influenza annually, pneumococcal and hepatitis B vaccines per guidelines.

Associated Autoimmune Disorders

Students should remember the autoimmune cluster associated with T1DM.

• Autoimmune thyroid disease: Hashimoto thyroiditis and Graves disease; screen with TSH (and anti‑TPO if indicated).
• Celiac disease: Associated with HLA‑DQ2/DQ8; screen with tissue transglutaminase IgA and total IgA.
• Pernicious anemia: Anti‑parietal cell and intrinsic factor antibodies; macrocytic anemia and low B12.
• Addison disease: Autoimmune adrenalitis; consider in unexplained hyponatremia, hyperkalemia, hypotension, or recurrent hypoglycemia.

Key Clinical Pearls for Exams and OSCEs

• 1. Absolute insulin deficiency: T1DM patients always require insulin; oral agents alone are inappropriate for long-term control.
• 2. DKA as a common first presentation: Any child or young adult with polyuria, polydipsia, weight loss, abdominal pain, and Kussmaul respirations should be assumed to have DKA until proven otherwise.
• 3. Autoantibodies help classification: GAD65, IA‑2, ZnT8, and IAA are supportive of T1DM and useful in atypical presentations.
• 4. C‑peptide differentiates types: Low or undetectable C‑peptide suggests T1DM; preserved or high C‑peptide suggests T2DM or other forms.
• 5. Honeymoon period: Shortly after diagnosis and insulin initiation, many patients experience a temporary reduction in insulin requirement due to partial β‑cell recovery; do not misclassify as T2DM.
• 6. Sick-day rules: Patients should not stop insulin when ill; they often need more insulin, frequent monitoring, and hydration to avoid DKA.
• 7. Hypoglycemia unawareness: Recurrent episodes blunt adrenergic warning symptoms; treat by relaxing glycemic targets temporarily and using CGM.
• 8. Early tight control pays off: Intensive therapy early in T1DM reduces microvascular complications and shows legacy benefits on macrovascular outcomes ("metabolic memory").
• 9. Pregnancy in T1DM: Requires preconception counseling, tight glycemic control, folate supplementation, and avoidance of teratogenic medications (e.g., ACE inhibitors, statins).
• 10. Always examine the feet: Annual foot exam with monofilament and vibration testing is essential to prevent ulcers and amputations.

Summary

Type 1 Diabetes Mellitus is an autoimmune disease characterized by destruction of pancreatic β‑cells, absolute insulin deficiency, and a high risk for acute (DKA, hypoglycemia) and chronic (micro‑ and macrovascular) complications. Diagnosis is based on standard glycemic criteria, with autoantibodies and C‑peptide levels supporting classification. Lifelong insulin therapy, structured education, and systematic screening for complications are central to care. For exams, focus on pathophysiology, classic clinical presentation, DKA management principles, insulin regimens, and prevention of long‑term complications.